Verona Pharma PLC
VRNA106.910USD
0.000
取引時間 （ET）15分遅れの株価
73.55B時価総額
損失額直近12ヶ月PER
詳細情報 Verona Pharma PLC 企業名
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Verona Pharma PLCの企業情報
企業コードVRNA
会社名Verona Pharma PLC
上場日Mar 30, 2005
最高経営責任者「CEO」Dr. David S. Zaccardelli, Pharm.D.
従業員数209
証券種類Depository Receipt
決算期末Mar 30
本社所在地Riverside
都市LONDON
証券取引所NASDAQ Global Market Consolidated
国United Kingdom
郵便番号SE1 2RE
電話番号442032834200
ウェブサイトhttps://www.veronapharma.com/
企業コードVRNA
上場日Mar 30, 2005
最高経営責任者「CEO」Dr. David S. Zaccardelli, Pharm.D.
Verona Pharma PLCの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+3488.37%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+3488.37%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Tue, Nov 11
更新時刻: Tue, Nov 11
株主統計
種類
株主統計
株主統計
比率
Janus Henderson Investors
7.12%
Perceptive Advisors LLC
6.39%
Darwin Global Management Ltd
4.79%
Frazier Life Sciences Management, L.P.
3.93%
Ali (Behbahani)
3.70%
他の
74.07%
株主統計
株主統計
比率
Janus Henderson Investors
7.12%
Perceptive Advisors LLC
6.39%
Darwin Global Management Ltd
4.79%
Frazier Life Sciences Management, L.P.
3.93%
Ali (Behbahani)
3.70%
他の
74.07%
種類
株主統計
比率
Hedge Fund
27.90%
Investment Advisor/Hedge Fund
23.85%
Investment Advisor
16.42%
Private Equity
10.42%
Research Firm
5.86%
Individual Investor
5.62%
Venture Capital
4.96%
Family Office
1.17%
Bank and Trust
0.41%
他の
3.39%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
467
76.61M
88.88%
-7.12M
2025Q2
423
82.86M
96.18%
-3.71M
2025Q1
406
83.91M
98.59%
+940.31K
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Janus Henderson Investors
6.13M
7.12%
+617.52K
+11.19%
Jun 30, 2025
Perceptive Advisors LLC
5.51M
6.39%
-1.06M
-16.09%
Jun 30, 2025
Darwin Global Management Ltd
4.13M
4.79%
+206.41K
+5.26%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
3.38M
3.93%
-73.90K
-2.14%
Jun 30, 2025
Ali (Behbahani)
3.19M
3.7%
+3.19M
--
Jan 16, 2025
RTW Investments L.P.
3.05M
3.54%
+203.08K
+7.13%
Jun 30, 2025
Eventide Asset Management, LLC
2.72M
3.15%
-178.11K
-6.16%
Jun 30, 2025
Goldman Sachs & Company, Inc.
2.61M
3.03%
+1.58M
+152.32%
Jun 30, 2025
New Enterprise Associates (NEA)
2.26M
2.63%
-425.43K
-15.82%
Jun 30, 2025
Summit Partners Public Asset Management, LLC
2.14M
2.49%
-178.83K
-7.70%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
AltShares Event-Driven ETF
3.15%
ProShares Merger ETF
2.4%
Global X Guru Index ETF
1.24%
ProShares Ultra Nasdaq Biotechnology
0.94%
Invesco Nasdaq Biotechnology ETF
0.91%
iShares Biotechnology ETF
0.56%
Rayliant Quantitative Developed Market Equity ETF
0.26%
Goldman Sachs Innovate Equity ETF
0.13%
iShares Intl Small Cap Equity Factor ETF
0.08%
Calvert International Responsible Index ETF
0.05%
詳細を見る
AltShares Event-Driven ETF
比率3.15%
ProShares Merger ETF
比率2.4%
Global X Guru Index ETF
比率1.24%
ProShares Ultra Nasdaq Biotechnology
比率0.94%
Invesco Nasdaq Biotechnology ETF
比率0.91%
iShares Biotechnology ETF
比率0.56%
Rayliant Quantitative Developed Market Equity ETF
比率0.26%
Goldman Sachs Innovate Equity ETF
比率0.13%
iShares Intl Small Cap Equity Factor ETF
比率0.08%
Calvert International Responsible Index ETF
比率0.05%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
